Innovent Biologics: Product revenue in the first half of 2026 exceeds 8.2 billion yuan, a year-on-year increase of over 55%.

Sinopharm Biotech has released an insider information announcement. In the first half of 2026, the company's product revenue exceeded RMB 8.2 billion, representing a year-on-year increase of over 55%. Among them, the product revenue for the second quarter reached over RMB 4.3 billion, with a year-on-year growth of approximately 60%.